Background/Synopsis: Fibroblast growth factor 21 (FGF21) is an endogenous metabolic
hormone that regulates energy expenditure, lipid, and carbohydrate metabolism. BIO89-100,
a glycoPEGylated FGF21 analog, is currently being evaluated in ENTRIGUE, a “Phase
2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and
Safety in Subjects with Severe Hypertriglyceridemia.”
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
